External analyst notes, journalism, and industry commentary cited with attribution.
Past catalysts on this ticker, reconciled against the announcement parse pipeline. Hover any row for the parsed outcome detail.
CHM-2101's own upcoming catalysts alongside class-defining historical readouts and upcoming primary completion dates in the same mechanism classes. Each event moves the broader thesis for CHM-2101. Showing past 6 months and next 12 months · 1 later hidden.
Same axes, same units. Discontinued and historical pivotal trials excluded; see Competitor Landscape below for the full set.
| Trial | Sponsor | Class | Phase / Line | Design | Primary endpoint | Dosing | Key eligibility | n |
|---|---|---|---|---|---|---|---|---|
| CHM-2101 | Chimeric Therapeutics | Autologous CDH17 CAR-T | Phase 1/22L+ | Open-label, single-arm, dose-escalation (Phase 1) followed by dose-expansion (Phase 2). Single intravenous infusion after lymphodepleting chemotherapy. | Safety and tolerability — dose-limiting toxicities at 28 days, incidence and grade of cytokine release syndrome and other adverse events — plus objective response rate (RECIST v1.1). | Single intravenous infusion of CHM-2101 following three days of fludarabine + cyclophosphamide lymphodepletion. Dose escalation across cohorts to define a recommended Phase 2 dose. | 135 patients (per ClinicalTrials.gov NCT06055439) |
Read-across commentary attached per trial. Phase ordering preserved within each group.
| Mechanism | Speed to patient | Manufacturing | Best approved result | Durability | Moat |
|---|---|---|---|---|---|
| Autologous CDH17 CAR-TAutologous cell | Weeks | Per-patient | None (solid) | Open question | First-in-class |
"Sponsor guided" dates come from IR materials and earnings calls; hover for the cited source. "CT.gov proxy" dates fall back to the registry primary completion date — actual readouts typically follow by 3-6 months.
| 135 |
| CT041 (satri-cel) Autologous Claudin18.2 CAR-T, gastric/GEJ (CT041-ST-01) | CARsgen Therapeutics | Autologous Claudin18.2 CAR-T | PHASE1/PHASE23L+ | Randomised (2:1 vs physician's choice), open-label, Phase 2 portion | Progression-free survival (independent review committee) | — | — | 192 |
| Anti-CDH17 CAR-T in CDH17-positive Advanced Solid Tumors | 920th Hospital of Joint Logistics Support Force, PLA (China) | Autologous CDH17 CAR-T | Early Phase 12L+ | Single-arm, open-label, Phase 1 | Incidence of adverse events within 52 weeks (incl. CRS, neurotoxicity) | — | — | 30 |
Read-acrossThe only other clinical-stage CDH17 CAR-T. Early-phase, single-centre academic study in China (30 pts); not a commercial competitor today, but the closest direct clinical read on the CDH17 target itself.
Read-acrossProof-of-concept that an autologous CAR-T can work in a GI solid tumour. Randomised Phase 2 met its PFS primary endpoint versus physician's choice and was published in The Lancet (2025). Different target (Claudin18.2, not CDH17) but the key external yardstick for CHM-2101.